The SCF ubiquitin ligases involved in hematopoietic lineage

Current Drug Targets

Volumn 13, Issue 13, 2012, Pages 1641-1648

  Kitagawa, Kyoko ^a   Kitagawa, Masatoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

E3 ligase; Fbw1; Fbw7; Hematopoiesis; Hematopoietic stem cells; Phosphorylation; Proteasome; SCF complex; Skp2; Ubiquitin

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BETA CATENIN; BORTEZOMIB; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1C; F BOX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEASOME; PROTEIN C MYB; PROTEIN MCL 1; PROTEIN P130; PROTEIN P21; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR TAL1; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL CYCLE; CELL LINEAGE; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MULTIPLE MYELOMA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; CELL LINEAGE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; SKP CULLIN F-BOX PROTEIN LIGASES;

EID: 84870224455     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803529974     Document Type: Article

References (81)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
2. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
3. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer Nat Rev Cancer 2008; 8: 438-449.
4. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
5. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW. Systematic analysis and nomenclature of mammalian F-box proteins. Gene Dev 2004; 18: 2573-2580.
6. Skaar JR, Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol 2009; 21: 816-824.
7. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 2004; 5: 739-751.
8. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci 2009; 100: 1374-1381.
9. Schroeder T. Hematopoietic stem cell heterogeneity: subtypes, not unpredictable behavior. Cell Stem Cell 2010; 6: 203-207.
10. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008; 135: 1118-1129.
11. Clements WK, Kim AD, Ong KG, Moore JC, Lawson ND, Traver D. A somitic Wnt16/Notch pathway specifies haematopoietic stem cells. Nature 2011; 474: 220-224.
12. Loeffler D, Kokkaliaris KD, Schroeder T. Wnt to notch relay signaling induces definitive hematopoiesis. Cell Stem Cell 2011; 9: 2-4.
13. Duncan AW, Rattis FM, DiMascio LN, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005; 6: 314-322.
14. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 2002; 21: 3414-3421.
15. Laurenti E, Varnum-Finney B, Wilson A, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008; 3: 611-624.
16. cip1/waf1. Science 2000; 287: 1804-1808.
17. cip1/waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells 2007; 25: 836-843.
18. Umemoto T, Yamato M, Nishida K, Yang J, Tano Y, Okano T.P57Kip2 is expressed in quiescent mouse bone marrow side population cells. BBRC 2005; 337: 14-21.
19. Matsumoto A, Takeishi S, Kanie T, et al. P57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell 2011; 9: 262-271.
20. kip1 Nat Med 2000; 6: 1235-1240.
21. Kip1 cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 2011; 9: 247-261.
22. Kip1 and p130 cooperate to regulate hematopoietic cell proliferation in vivo. Mol Cell Biol 2006; 26: 6170-6184.
23. Rodriguez S, Wang L, Mumaw C, et al. The SKP2 E3 ligase regulates basal homeostasis and stress-induced regeneration of HSCs. Blood 2011; 117: 6509-6519.
24. Wang J, Han F, Wu J, et al. The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood 2011; 118: 5429-5438.
25. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 1996; 86: 47-57.
26. Anantharaman A, Lin, IJ, Barrow J, et al. Role of Helix-Loop- Helix proteins during differentiation of erythroid cells. Mol Cell Biol 2011; 31: 1332-1343.
27. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004; 5: 587-596.
28. Nie L, Xu M, Vladimirova A, Sun XH. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 2003; 22: 5780-5792.
29. Nie L, Wu H, Sun XH. Ubiquitination and degradation of Tal1/SCL are induced by notch signaling and depend on Skp2 and CHIP. J Biol Chem 2008; 283: 684-692.
30. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nature Rev 2007; 7: 823-833.
31. Liu H, Takeda S, Cheng EH, Hsieh JJ. Biphasic MLL takes helm at cell cycle control. Cell Cycle 2008; 7: 428-435.
32. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695-5707.
33. Cozzio A, Passegué E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from selfrenewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029-3035.
34. Liu H, Takeda S, Kumar R, et al. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 2010; 467: 343-346.
35. Akiyama T. Wnt/β-catenin signaling. Cytokine Growth Factor Rev 2000; 11: 273-282.
36. Hart M, Concordet JP, Lassot I, et al. The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr Biol 1999; 9: 207-210.
37. Kitagawa M, Hatakeyama S, Shirane M, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J 1999; 18: 2401-2410.
38. Baba Y, Yokota T, Spits H, Garrett KP, Hayashi S, Kincade PW. Constitutively active β-Catenin promotes expansion of multipotent hematopoietic progenitors in culture. J Immunol 2006; 177: 2294-2303.
39. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 2006; 7: 1048-1056.
40. Scheller M, Huelsken J, Rosenbauer F, et al. Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation. Nat Immunol 2006; 7: 1037-1047.
41. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414.
42. Zhao C, Blum J, Chen A, et al. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528-541.
43. Jeannet G, Scheller M, Scarpellino L, et al. Long-term, multilineage hematopoiesis occurs in the combined absence of β-catenin andf β-catenin. Blood 2008; 111: 142-149.
44. Koch U, Wilson A, Cobas M, Kemler R, Macdonald HR, Radtke F. Simultaneous loss of β- and β-catenin does not perturb hematopoiesis or lymphopoiesis. Blood 2008; 111: 160-164.
45. Nemeth MJ, Mak KK, Yang Y, Bodine DM. β-Catenin expression in the bone marrow microenvironment is required for long-term maintenance of primitive hematopoietic cells. Stem Cells 2009; 27: 1109-1119.
46. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-βB in hematologic malignancies. Cell Death Differ 2006; 13: 748-758.
47. Bottero V, Withoff1 S, Verma IM. NF-βB and the regulation of hematopoiesis. Cell Death and Diff 2006; 13: 785-797.
48. Hatakeyama S, Kitagawa M, Nakayama K, et al. Ubiquitindependent degradation of IβBβis mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci USA 1999; 96: 3859-3863.
49. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007; 8: 584-591.
50. Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: An attractive target for cancer therapy. BBA 2012; 1825: 64-76.
51. Margottin F, Bour SP, Durand H, et al. A novel human WD protein, h-βTrCP, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998; 1: 565-574.
52. Dougras JL, Viswanathan K, McCarroll MN, Gustin JK, Früh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a β TrCPdependent mechanism. J Virol 2009; 83: 7931-7947.
53. Dubé M, Bego MG, Paquay C, Cohen ÉA. Modulation of HIV-1- host interaction: role of the Vpu accessory protein. Retrovirology 2010; 7: 114.
54. Reavie L, Della Gatta G, Crusio K, et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligasesubstrate complex. Nat Immunol 2010; 11: 207-215.
55. Matsuoka S, Oike Y, Onoyama I, I et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008; 22: 986-991.
56. Thompson BJ, Jankovic V, Gao J, et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med 2008; 205: 1395-1408.
57. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008; 321: 1499-1502.
58. Chen C, Liu Y, Liu Y, Zheng P. MTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2009; 2:75.
59. Li J. Quiescence regulators for hematopoietic stem cell. Exp Hematol 2011; 39: 511-520.
60. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011; 208: 1931-1935.
61. Stier S, Cheng T, Dombkowski D, Carlesso N, Scadden DT. Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood 2002; 99: 2369-2378.
62. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-βB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
63. Kumano K, Chiba S, Shimizu K, et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood 2001; 98: 3283-3289.
64. Malyukova A, Dohda T, von der Lehr N, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-5616.
65. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.
66. Zúñiga-Pflücker JC. T-cell development made simple. Nat Rev Immunol 2004; 4: 67-72.
67. Onoyama I, Tsunematsu R, Matsumoto A, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 2007; 204: 2875-2888.
68. Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G, Frampton J. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J 2003; 22: 4478-4488.
69. Anderson MK. At the crossroads: diverse roles of early thymocyte transcriptional regulators. Immunol Rev 2006; 209: 191-211.
70. Kanei-Ishii C, Nomura T, Takagi T, Watanabe N, Nakayama KI, Ishii S. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J Biol Chem 2008; 283: 30540-30548.
71. Kitagawa K, Hiramatsu Y, Uchida C, et al. Fbw7 promotes ubiquitin- dependent degradation of c-Myb: involvement of GSK3- mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene 2009; 28: 2393-2405.
72. Lahortiga I, de Keersmaecker K, Van Vlierberghe P, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007; 39: 593-595.
73. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene 1999; 18: 3017-3033.
74. Sakamoto H, Dai G, Tsujino K, et al. Proper levels of c-Myb are discretely defined at distinct steps of hematopoietic cell development. Blood 2006; 108: 896-903.
75. Metcalf D, Carpinelli MR, Hyland C, et al. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood 2005; 105: 3480-3487.
76. Craig, RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16: 444-454.
77. Gui J, Morales AJ, Maxey SE, et al. MCL1 increases primitive thymocyte viability in female mice and promotes thymic expansion into adulthood. Int Immunol 2011; 23: 647-659.
78. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085-1095.
79. Ding Q, He X, Hsu JM, et al. Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007; 27: 4006-4017.
80. Inuzuka H, Shaik S, Onoyama I, et al. SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109.
81. Kitagawa K, Kotake Y, Hiramatsu Y, et al. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Cell Div 2010; 5: 27.